New targets for triple-negative breast cancer.
Christina I. Herold(Beth Israel Deaconess Medical Center), Carey K. Anders(Duke University)
PubMed
September 1, 2013
Cited by 29
Related Papers
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
Brain metastases
|Nature Reviews Disease Primers|2019|1.1k
Young Age at Diagnosis Correlates With Worse Prognosis and Defines a Subset of Breast Cancers With Shared Patterns of Gene Expression
|Journal of Clinical Oncology|2008|917
Breast Cancer Before Age 40 Years
|Seminars in Oncology|2009|795
Biology, Metastatic Patterns, and Treatment of Patients with Triple-Negative Breast Cancer
|Clinical Breast Cancer|2009|644